ES2747303T3 - Cristal de ácido 7-{(3S,4S)-3-[(ciclopropilamino)metil]-4-fluoropirrolidin-1-il}-6-fluoro-1-(2-fluoroetil)-8-metoxi-4-oxo-1,4-dihidroquinolin-3-carboxílico - Google Patents

Cristal de ácido 7-{(3S,4S)-3-[(ciclopropilamino)metil]-4-fluoropirrolidin-1-il}-6-fluoro-1-(2-fluoroetil)-8-metoxi-4-oxo-1,4-dihidroquinolin-3-carboxílico Download PDF

Info

Publication number
ES2747303T3
ES2747303T3 ES16177827T ES16177827T ES2747303T3 ES 2747303 T3 ES2747303 T3 ES 2747303T3 ES 16177827 T ES16177827 T ES 16177827T ES 16177827 T ES16177827 T ES 16177827T ES 2747303 T3 ES2747303 T3 ES 2747303T3
Authority
ES
Spain
Prior art keywords
crystals
hydrochloride salt
fluoroethyl
oxo
dihydroquinolin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES16177827T
Other languages
English (en)
Spanish (es)
Inventor
Ichiro Araya
Akinori Goto
Wataru Minagawa
Keiko Funada
Muneki Nagao
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Kyorin Pharmaceutical Co Ltd
Original Assignee
Kyorin Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=48289529&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ES2747303(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Kyorin Pharmaceutical Co Ltd filed Critical Kyorin Pharmaceutical Co Ltd
Application granted granted Critical
Publication of ES2747303T3 publication Critical patent/ES2747303T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47Quinolines; Isoquinolines
    • A61K31/4709Non-condensed quinolines and containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07BGENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
ES16177827T 2011-11-10 2012-11-09 Cristal de ácido 7-{(3S,4S)-3-[(ciclopropilamino)metil]-4-fluoropirrolidin-1-il}-6-fluoro-1-(2-fluoroetil)-8-metoxi-4-oxo-1,4-dihidroquinolin-3-carboxílico Active ES2747303T3 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2011246209 2011-11-10
JP2012071739 2012-03-27

Publications (1)

Publication Number Publication Date
ES2747303T3 true ES2747303T3 (es) 2020-03-10

Family

ID=48289529

Family Applications (2)

Application Number Title Priority Date Filing Date
ES16177827T Active ES2747303T3 (es) 2011-11-10 2012-11-09 Cristal de ácido 7-{(3S,4S)-3-[(ciclopropilamino)metil]-4-fluoropirrolidin-1-il}-6-fluoro-1-(2-fluoroetil)-8-metoxi-4-oxo-1,4-dihidroquinolin-3-carboxílico
ES12846895.6T Active ES2621664T3 (es) 2011-11-10 2012-11-09 Cristal de ácido 7-{(3S,4S)-3-[(ciclopropilamino)metil]-4-fluoropirrolidin-1-il}-6-fluoro-1-(2-fluoroetil)-8-metoxi-4-oxo-1,4-dihidroquinolin-3-carboxílico

Family Applications After (1)

Application Number Title Priority Date Filing Date
ES12846895.6T Active ES2621664T3 (es) 2011-11-10 2012-11-09 Cristal de ácido 7-{(3S,4S)-3-[(ciclopropilamino)metil]-4-fluoropirrolidin-1-il}-6-fluoro-1-(2-fluoroetil)-8-metoxi-4-oxo-1,4-dihidroquinolin-3-carboxílico

Country Status (17)

Country Link
US (3) US9090587B2 (https=)
EP (2) EP3112359B1 (https=)
JP (4) JP5871948B2 (https=)
KR (2) KR20140098074A (https=)
CN (2) CN103930414B (https=)
AU (1) AU2016273899B2 (https=)
BR (1) BR112014010765B1 (https=)
CA (1) CA2855022C (https=)
ES (2) ES2747303T3 (https=)
IN (1) IN2014DN03277A (https=)
MX (1) MX375073B (https=)
NZ (1) NZ623808A (https=)
RU (2) RU2017109814A (https=)
SA (1) SA112330992B1 (https=)
SG (2) SG10201608167UA (https=)
TW (1) TWI547492B (https=)
WO (1) WO2013069297A1 (https=)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12594418B2 (en) 2011-03-10 2026-04-07 Electrocore, Inc. Devices and methods for nerve stimulation
SA112330992B1 (ar) * 2011-11-10 2015-09-13 كيورين فارماسوتيكال كو.، ليمتد صورة متبلرة من 7-{(s4، s3)-3-[(سيكلو بروبيل أمينو) ميثيل]-4-فلورو بيروليدين-1-يل}-6-فلورو-1-(2-فلورو إيثيل)- 8-ميثوكسي-4-أوكسو-1، 4-داي هيدرو كينولين-3- حمض كربوكسيلي
WO2014174847A1 (ja) * 2013-04-25 2014-10-30 杏林製薬株式会社 固形医薬組成物
JP6349306B2 (ja) * 2013-04-25 2018-06-27 杏林製薬株式会社 錠剤
US9603804B2 (en) 2013-04-25 2017-03-28 Kyorin Pharmaceutical Co., Ltd. Solid pharmaceutical composition
GB201402071D0 (en) 2014-02-07 2014-03-26 Galapagos Nv Novel salts and pharmaceutical compositions thereof for the treatment of inflammatory disorders
US10154993B2 (en) 2014-10-23 2018-12-18 Kyorin Pharmaceutical Co., Ltd. Solid pharmaceutical composition
EP3210608A4 (en) * 2014-10-23 2018-06-20 Kyorin Pharmaceutical Co., Ltd. Solid pharmaceutical composition
WO2016148066A1 (ja) 2015-03-13 2016-09-22 杏林製薬株式会社 呼吸器感染症治療剤
WO2016195021A1 (ja) * 2015-06-02 2016-12-08 杏林製薬株式会社 水性液剤
EP3305294A4 (en) * 2015-06-02 2019-02-20 Kyorin Pharmaceutical Co., Ltd. AQUEOUS MEDICINE
JP6675396B2 (ja) * 2015-06-02 2020-04-01 杏林製薬株式会社 水性液剤
BR112019025960A2 (pt) 2017-06-16 2020-11-03 Kyorin Pharmaceutical Co., Ltd. agente terapêutico para pneumonia aspirativa, supuração pulmonar ou abcesso pulmonar
TW202415375A (zh) 2017-06-16 2024-04-16 日商杏林製藥股份有限公司 吸入性肺炎、肺化膿症或肺膿瘍之治療劑
GB201808575D0 (en) 2018-05-24 2018-07-11 Galapagos Nv Methods for the treatment of psoriatic arthrits

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA944369B (en) * 1993-08-27 1995-02-13 Hokuriku Seuyaku Co Ltd 5-amino-8-methyl-7-pyrrolidinylquinoline-3-carboxylic acid derivative
CN1158846A (zh) * 1995-05-09 1997-09-10 昆山市康壮达兽药厂 盐酸氟哌酸的合成工艺
US20030124028A1 (en) 2001-08-10 2003-07-03 Carlson Eric D. Apparatuses and methods for creating and testing pre-formulations and systems for same
WO2003076428A1 (en) * 2002-03-08 2003-09-18 Daiichi Pharmaceutical Co., Ltd. Quinolonecarboxylic acid derivative
CN100410249C (zh) 2003-09-10 2008-08-13 杏林制药株式会社 7-(4-取代-3-环丙基氨基甲基-1-吡咯烷基)喹诺酮羧酸衍生物
CN101003540A (zh) * 2006-01-18 2007-07-25 广州白云山制药股份有限公司广州白云山制药总厂 一种抗感染化合物和用途
SA112330992B1 (ar) * 2011-11-10 2015-09-13 كيورين فارماسوتيكال كو.، ليمتد صورة متبلرة من 7-{(s4، s3)-3-[(سيكلو بروبيل أمينو) ميثيل]-4-فلورو بيروليدين-1-يل}-6-فلورو-1-(2-فلورو إيثيل)- 8-ميثوكسي-4-أوكسو-1، 4-داي هيدرو كينولين-3- حمض كربوكسيلي

Also Published As

Publication number Publication date
US9328089B2 (en) 2016-05-03
RU2615509C2 (ru) 2017-04-05
SG10201608167UA (en) 2016-11-29
EP3112359B1 (en) 2019-08-21
US9090587B2 (en) 2015-07-28
JP6818719B2 (ja) 2021-01-20
CN104945375A (zh) 2015-09-30
AU2016273899B2 (en) 2017-07-27
EP2778159A1 (en) 2014-09-17
JP6349435B2 (ja) 2018-06-27
IN2014DN03277A (https=) 2015-05-22
EP2778159B1 (en) 2017-03-01
NZ623808A (en) 2015-07-31
US20150284361A1 (en) 2015-10-08
BR112014010765A2 (pt) 2017-06-13
MX375073B (es) 2025-03-06
BR112014010765B1 (pt) 2020-07-14
JP2018158949A (ja) 2018-10-11
RU2017109814A3 (https=) 2020-04-08
KR102162208B1 (ko) 2020-10-06
TWI547492B (zh) 2016-09-01
CN103930414A (zh) 2014-07-16
EP2778159A4 (en) 2015-06-03
AU2012337206A1 (en) 2014-05-22
JP5871948B2 (ja) 2016-03-01
RU2017109814A (ru) 2019-01-23
KR20140098074A (ko) 2014-08-07
AU2012337206A8 (en) 2016-09-22
CA2855022C (en) 2019-05-07
TW201332991A (zh) 2013-08-16
AU2012337206B2 (en) 2016-09-15
CA2855022A1 (en) 2013-05-16
JP2017160243A (ja) 2017-09-14
USRE47785E1 (en) 2019-12-31
US20140288310A1 (en) 2014-09-25
CN104945375B (zh) 2017-07-04
WO2013069297A1 (ja) 2013-05-16
SA112330992B1 (ar) 2015-09-13
KR20190065456A (ko) 2019-06-11
JPWO2013069297A1 (ja) 2015-04-02
JP6514069B2 (ja) 2019-05-15
EP3112359A1 (en) 2017-01-04
ES2621664T3 (es) 2017-07-04
JP2016027045A (ja) 2016-02-18
RU2014123567A (ru) 2015-12-20
CN103930414B (zh) 2016-01-20
AU2016273899A1 (en) 2017-01-12
SG11201401817TA (en) 2014-08-28

Similar Documents

Publication Publication Date Title
ES2747303T3 (es) Cristal de ácido 7-{(3S,4S)-3-[(ciclopropilamino)metil]-4-fluoropirrolidin-1-il}-6-fluoro-1-(2-fluoroetil)-8-metoxi-4-oxo-1,4-dihidroquinolin-3-carboxílico
CN114728899A (zh) 新型三苯基化合物盐
ES2302949T3 (es) Pirrolopirimidina y derivados de pirrolopirimidina sustituidos con un grupo amino ciclico.
MX2015004787A (es) Compuestos antiviricos para el virus sincitial respiratorio.
ES2909198T3 (es) Proceso para la preparación de pleuromutilinas
ES2828636T3 (es) Sal agonista de receptores opioides (MOR), forma cristalina I de la sal de fumarato de la misma y método de preparación de las mismas
ES2699884T3 (es) Nuevo compuesto cristalino de arilalquilamina y método para producir el mismo
US10406149B2 (en) Aqueous liquid formulation
AU2012337206B8 (en) 7-{(3S,4S)-3-[(cyclopropylamino)methyl]-4-fluoropyrrolidine-1-yl}-6-fluoro-1-(2-fluoroethyl)-8-methoxy-4-oxo-1,4-dihydroquinoline-3-carboxylic acid crystal
MX2014005007A (es) Cristal del acido 7-{(3s,4s)-3-[(ciclopropilamino)metil]-4-fluorop irrolidin-1-il}-6-fluoro-1-(fluoroetil)-8-metoxi-4-oxo-1,4-dihidr oquinolin-3-carboxilico.
TW202545925A (zh) 螺環kif18a抑制劑